Arrivent Biopharma . Common Stock Stock Forecast

Buy or Hold candidate since May 29, 2026 Gain 13.97%

The Arrivent Biopharma, Inc. Common Stock stock price fell by -0.691% on the last day (Wednesday, 1st Jul 2026) from $34.74 to $34.50. During the last trading day the stock fluctuated 3.12% from a day low at $34.34 to a day high of $35.41. The price has risen in 8 of the last 10 days and is up by 13.75% over the past 2 weeks. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -332 thousand shares and in total, 307 thousand shares were bought and sold for approximately $10.59 million.

The stock lies in the upper part of a wide and strong rising trend in the short term, and this may normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break-up at the top trend line at $34.83 will firstly indicate a stronger rate of rising. Given the current short-term trend, the stock is expected to rise 18.17% during the next 3 months and, with a 90% probability hold a price between $33.91 and $41.16 at the end of this 3-month period.

AVBP Signals & Forecast

The Arrivent Biopharma, Inc. Common Stock stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $33.89 and $30.31. A breakdown below any of these levels will issue sell signals. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Tuesday, June 30, 2026, and so far it has fallen -0.691%. Further fall is indicated until a new bottom pivot has been found. Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.

Support, Risk & Stop-loss for Arrivent Biopharma, Inc. Common Stock stock

Arrivent Biopharma, Inc. Common Stock finds support from accumulated volume at $34.00 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $1.07 between high and low, or 3.12%. For the last week, the stock has had daily average volatility of 4.88%.

Our recommended stop-loss: $33.18 (-3.82%) (This stock has medium daily movements and this gives medium risk. There is a sell signal from a pivot top found 1 day ago.)

Trading Expectations (AVBP) For The Upcoming Trading Day Of Thursday 2nd

For the upcoming trading day on Thursday, 2nd we expect Arrivent Biopharma, Inc. Common Stock to open at $34.75, and during the day (based on 14 day Average True Range), to move between $33.65 and $35.35, which gives a possible trading interval of +/-$1.71 (+/-5.07%) up or down from last closing price. If Arrivent Biopharma, Inc. Common Stock takes out the full calculated possible swing range there will be an estimated 5.07% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $34.74 (0.70%) than the support at $34.00 (1.45%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is Arrivent Biopharma, Inc. Common Stock stock A Buy?

Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Arrivent Biopharma, Inc. Common Stock stock to perform well in the short-term. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Strong Buy to a Buy candidate.

Current score: 2.942 Buy Candidate Downgraded

Predicted Fair Opening Price

Predicted fair opening price on July 2, 2026 - $34.75 ( 0.725%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker*
*Your capital is at risk